Broker recommendations for Abbott Laboratories
The Abbott Laboratories stock is rated at 1.357143 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Friday 29 May, 2020 by a total of 21 brokers. This means that the consensus of the 21 different brokers is leaning toward to buy/moderate buy.
1 (4.76%) Underweight
1 (4.76%) Hold
3 (14.29%) Overweight
2 (9.52%) Buy
Price target by analysts
The 16 latest analyst estimates, per Monday 20 July, 2020, show the following high, low and average price targets.
Target Average: 106.38 USD
Target High: 116 USD
Target Low: 84 USD
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic’s Blowout Quarter
Thursday, 30 July 2020, 10:09:00
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals Corp …
Worldwide Dietary Supplements Industry to 2026 – Featuring Amway, Abbott Laboratories & Bayer Among Others
Tuesday, 28 July 2020, 23:00:00
DUBLIN, July 28, 2020 /PRNewswire/ — The “Global Dietary Supplements Market: Consumer Behavior Analysis by Countries, Buying Pattern Analysis, Demographics, Trends Analysis, Survey Findings and Results, Leading Companies and their Market Strategies” report has been added to…
— PR Newswire
The U.S. has more COVID-19 testing than most. So why is it falling so short?
Monday, 27 July 2020, 12:04:07
By Allison Martell and Ned Parker (Reuters) – The United States might have more COVID-19 testing capacity than any other country. So why have we seen laboratories overwhelmed and many patients again waiting a week or more for results? At the heart of the crisis is a reliance by public and private labs on automated testing equipment that locks them in to using proprietary chemical kits and other tools made by a handful of manufacturers. The result: as infection rates spike nationwide, many labs aren’t running anywhere near capacity because of supply-chain bottlenecks, according to Reuters interviews with 16 hospital, state, commercial and academic labs and an analysis of state and city procurement plans. A few companies – Cepheid, Hologic Inc, Roche and Abbott Laboratories – dominate this market. Their machines run on chemical kits and disposable plastic parts like sample plates and pipettes that only they sell, much like branded printer cartridges. The vendors are in an impossible situation right now where they can’t say yes to everyone, said Geoffrey Baird, who runs the medical laboratory at the University of Washington.
— Swiss Info
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
Friday, 24 July 2020, 09:15:00
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc …
Friday, 24 July 2020, 01:30:00
Technavio has been monitoring the global helicobacter pylori diagnostics market size and it is poised to grow by USD 209.59 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200723005618/en/ Technavio has announced its latest market research report titled Global Helicobacter Pylori Diagnostics Market 2020-2024 (Graphic: Business Wire) Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
— Benzinga Feeds